Table of Contents

company-logo

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Salarius Pharmaceuticals Dividend Announcement

• Salarius Pharmaceuticals does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Salarius Pharmaceuticals dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Salarius Pharmaceuticals Dividend History

Salarius Pharmaceuticals Dividend Yield

Salarius Pharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Salarius Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

Salarius Pharmaceuticals Financial Ratios

P/E ratio-0.14
PEG ratio0.20
P/B ratio0.38
ROE-148.64%
Payout ratio0.00%
Current ratio2.98
Quick ratio2.98
Cash Ratio2.78

Salarius Pharmaceuticals Dividend FAQ

Does Salarius Pharmaceuticals stock pay dividends?
Salarius Pharmaceuticals does not currently pay dividends to its shareholders.
Has Salarius Pharmaceuticals ever paid a dividend?
No, Salarius Pharmaceuticals has no a history of paying dividends to its shareholders. Salarius Pharmaceuticals is not known for its dividend payments.
Why doesn't Salarius Pharmaceuticals pay dividends?
There are several potential reasons why Salarius Pharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Salarius Pharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Salarius Pharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Salarius Pharmaceuticals a dividend aristocrat?
Salarius Pharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Salarius Pharmaceuticals a dividend king?
Salarius Pharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Salarius Pharmaceuticals a dividend stock?
No, Salarius Pharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Salarius Pharmaceuticals stocks?
To buy Salarius Pharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Salarius Pharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.